Granulomatous hepatitis after intravesical BCG treatment for bladder cancer.
Intravesical bacillus Calmette-Guerin (BCG) is used in patients with urinary bladder carcinoma. Although it is generally well tolerated, granulomatous hepatitis is a rare but serious complication. We report a 42-year-old man and a 56-year-old man who developed granulomatous hepatitis following intravesical BCG. One of them was treated successfully with antitubercular therapy; the other died because of BCG sepsis and multi-organ failure.
Ersoy
Osman
O
Department of Gastroenterology, Hacettepe University Faculty of Medicine, Ankara, Turkey. roersoy@tnn.net
Aran
Rasit
R
Aydinli
Musa
M
Yonem
Ozlem
O
Harmanci
Ozgur
O
Akdogan
Bulent
B
Pinar
Ahmet
A
Sokmensuer
Cenk
C
Bayraktar
Yusuf
Y
D000283:Administration, Intravesical; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects*; D001707:Biopsy, Needle; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D017809:Fatal Outcome; D006801:Humans; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014386:Tuberculosis, Hepatic / Q000188:drug therapy / Q000382:microbiology*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000995:Antitubercular Agents; D001500:BCG Vaccine